Apollo, Max in focus as Supreme Court seeks 16% mark-up on hospital medicines
India's Supreme Court sought a uniform 16% mark-up on hospital medicines, including patented medicines. The next hearing is scheduled for October 12, 2026. Brokerages say package pricing and increases in other charges could cushion potential earnings pressure.
Read the source at Financial Express · BrandWagonThe numbers
| Goldman Sachs potential EBITDA impact: | 2-7% |
|---|---|
| Jefferies potential EBITDA impact: | 2-5% |
| Medicines outside price-control framework: | 80-82% |
| Goldman Sachs offsetting price increase: | 1-2% |
| December 2025 hospital package expense share: | 52% |
| Jefferies Fortis Healthcare target upside: | 46% |
Why it matters to operators and investors
In hospital acquisition diligence, scrutinize dependence on medicine margins and the sustainability of pricing offsets before underwriting earnings and valuations.
What to watch next
- The Supreme Court's directions at the October 12 hearing
- An order specifying implementation timing and coverage of patented drugs
- Apollo or Max announcements of revised package or non-medicine charges
- Hospital disclosures quantifying medicine-margin losses and pricing offsets
- EBITDA-impact guidance relative to Goldman Sachs' estimated 2–7% hit
Likely next moves
The desk's read of what comes next — analysis, not reported by the source.
- Apollo and Max are likely to review medicine margins and package economics while awaiting clarity on whether the proposed mark-up becomes binding.
- Apollo and Max may shift part of the earnings pressure into package prices or non-medicine charges if the restriction is imposed.
- Goldman Sachs is likely to reassess its earnings-impact estimate once the court clarifies the scope and hospitals disclose their pricing responses.
- Patients at Apollo and Max may see smaller savings on total treatment bills than on medicine charges if hospitals reprice other components.
The counter-case
If a uniform 16% medicine mark-up becomes binding, Apollo and Max could lose high-margin pharmacy earnings, including on patented drugs. The estimated 2–7% EBITDA hit could understate downside if implementation is broad and insurers, patients or regulators resist offsetting increases in other hospital charges. Package pricing is a potential cushion, not a guaranteed escape.